P392: Body mass index has no effect on treatment response in Crohn's disease patients with moderate disease activity who receive adalimumab
ECCO '19 Copenhagen
2019
P393: Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on infliximab
ECCO '19 Copenhagen
2019
P394: Contribution of the CDEIS in the new therapeutic approach of Crohn's disease
ECCO '19 Copenhagen
2019
P395: Postoperative immunosuppressive therapies decrease the risk of second intestinal surgery in patients with Crohn’s disease: a retrospective cohort study
ECCO '19 Copenhagen
2019
P397: Autologous stem cell transplantation in refractory Crohn's disease: evaluation of a modified mobilisation regimen and analyses of the cost-effectiveness
ECCO '19 Copenhagen
2019
P398: Leptin controls immune cell composition and activity in acquired generalised lipodystrophy with combined Crohn’s disease
ECCO '19 Copenhagen
2019
P399: Cost-effectiveness of utilising proactive Infliximab therapeutic drug monitoring for inflammatory bowel disease in routine clinical practice
ECCO '19 Copenhagen
2019
P400: Discordance in patient and physician perspectives and priorities in communication and management of ulcerative colitis: results of the European ulcerative colitis narrative survey
ECCO '19 Copenhagen
2019
P401: Association between induction vedolizumab drug levels and therapy outcome in inflammatory bowel disease
ECCO '19 Copenhagen
2019
P402: Systemic steroids vs. local acting steroids: Relative risk for corticosteroid-related adverse events
ECCO '19 Copenhagen
2019
P403: Intravenous iron infusion in inflammatory bowel disease: efficacy and ferro-economics
ECCO '19 Copenhagen
2019
P404: Stopping 5-aminosalicylates in Crohn’s disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts
ECCO '19 Copenhagen
2019
P405: Sustainability of biologic therapies is less in UC than CD patients independent of prior biologic experience
ECCO '19 Copenhagen
2019
P406: General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies
ECCO '19 Copenhagen
2019
P407: Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study
ECCO '19 Copenhagen
2019
P408: Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P409: Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring
ECCO '19 Copenhagen
2019